

Request for Prior Authorization ANTIEMETIC-5HT3 RECEPTOR ANTAGONISTS/ SUBSTANCE P NEUROKININ PRODUCTS

FAX Completed Form To | (800) 574-2515

Provider Help Desk | (877) 776-1567

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax ND	С		

Prior authorization is required for preferred Antiemetic-5HT3 Receptor Antagonists/Substance P Neurokinin medications for quantities exceeding the dosage limits provided in parentheses. Payment for Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents beyond this limit will be considered on an individual basis after review of submitted documentation.

Prior authorization will be required for all non-preferred Antiemetic-5HT3 Receptor Antagonists/ Substance P Neurokinin medications beginning the first day of therapy. Payment for non-preferred medications will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent in this class. Note: Aprepitant (Emend®) will only be payable when used in combination with other antiemetic agents (5-HT3 medication and dexamethasone) for patients receiving highly emetogenic cancer chemotherapy.

Emend 80mg capsules (8)				
	🗌 Akynzeo (2)	🗌 Sancuso Patch		
Emend 125mg capsules (4)	🗌 Aloxi 0.25mg/5mL (4 vials)	🗌 Zuplenz		
Ondansetron 4mg tablets (60)	Anzemet 50mg & 100mg tablets (5	i)		
Ondansetron 8mg tablets (60)	Anzemet 100mg/5mL (4 vials)			
Ondansetron 2mg/mL (4 – 20mL vials)	Anzemet 12.5mg/0.625mL (8 ampules)			
Ondansetron 2mg/mL (8 – 2mL vials)	Aprepitant			
Ondansetron ODT 4mg tablets (60)	Emend Oral Suspension			
Ondansetron ODT 8mg tablets (60)	Granisetron Img tablets (8)			
Ondansetron oral solution 4mg/5mL	Granisetron Img/mL (8 vials)			
(50mL/month)	Granisetron 4mg/4mL (2 vials)			
Strength Dosage I	nstructions Quantity Da	ys Supply		
Diagnosis:				
Medical reasoning for therapy exceeding dosage limits:				
riedical reasoning for therapy exceeding dosage i				
Reason for use of Non-Preferred drug requiring				
	prior approval:			
Reason for use of Non-Preferred drug requiring Attach lab results and other documentation a	prior approval: is necessary.			
Reason for use of Non-Preferred drug requiring	prior approval: is necessary.	of submission		
Reason for use of Non-Preferred drug requiring Attach lab results and other documentation a	prior approval: is necessary.	of submission		
Reason for use of Non-Preferred drug requiring Attach lab results and other documentation a Prescriber signature (Must match prescriber listed a	prior approval: as necessary. above.) Date			
Reason for use of Non-Preferred drug requiring Attach lab results and other documentation a	prior approval:	ent from the standpoint of medical necessity o		
Reason for use of Non-Preferred drug requiring Attach lab results and other documentation a Prescriber signature (Must match prescriber listed a IMPORTANT NOTE: In evaluating requests for prior a	prior approval:	nt from the standpoint of medical necessity o nid. It is the responsibility of the provider who		
Reason for use of Non-Preferred drug requiring	prior approval:			